Drug Development Pharma - April 26, 2017
NeuroVive presents preclinical findings
NeuroVive Pharmaceutical announces positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model. NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also in the experimental MCD NASH […]
Clinical Trials - April 23, 2017
NeuroVive continues clinical development with NeuroSTAT for TBI
NeuroVive Pharmaceutical announces positive results from clinical and preclinical studies with its drug NeuroSTAT for the prevention of the sequelae of traumatic brain injury (TBI) and is now preparing for the next clinical study with NeuroSTAT. The combined positive outcome of the results from the clinical phase IIa CHIC (Copenhagen Head Injury Cyclosporine) study, conducted […]
Agreement - February 24, 2017
NeuroVive appoints scientific advisors and enters research agreement
NeuroVive Pharmaceutical announces two new research agreements and the appointment of Professor Philippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scientific advisors. The aim of the agreements is to further explore NeuroVive’s new drug compounds in development for the treatment of NASH and hepatocellular carcinoma (HCC). In the new collaboration with Philippe […]
Clinical Trials - February 6, 2017
NeuroVive presents preclinical data
NeuroVive Pharmaceutical presents preclinical data from a new generation of sanglifehrin-based compounds with potent inhibitory effects on hepatocellular carcinoma (HCC) cells and anti-cancer activity in an experimental model of HCC at the scientific conference EASL HCC Summit held in Geneva, Switzerland, 2-5 February, 2017. The company has explored anti-cancer effects in a new proprietary subset […]
Agreement - January 24, 2017
NeuroVive in new research agreement
NeuroVive Pharmaceutical has signed a preclinical collaboration agreement with the Children’s Hospital of Philadelphia (CHOP) and Marni J. Falk, M.D., a US opinion leader in the mitochondrial medicine field. Dr. Falk’s research team at CHOP will evaluate compounds from NeuroVive’s research program, NVP015, in certain experimental disease models. The research team will study energy metabolism […]
Clinical Trials - January 20, 2017
NeuroVive presents positive preclinical data
NeuroVive Pharmaceutical announces that an abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summitto take place in Geneva, Switzerland, 2-5 February, 2017. In preclinical studies, the NeuroVive research team and its international collaborators have shown that a sub-set of these […]
